Eryaspase Shows Promise for Metastatic Pancreatic Cancer Patients

LW Newsfeed
Data presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid shows that Erytech Pharma’s eyraspase (graspa) could potentially be an effective treatment in patients with metastatic pancreatic adenocarcinoma.

The open-label, multi-center, randomized Phase 2b clinical study conducted in France assessed the efficacy of eryaspase, a drug which consists of L-asparaginase (L-ASP) encapsulated in red blood cells, as a second-line treatment in combination with chemotherapy in 141 patients with metastatic pancreatic cancer. Read more . . .

image_printPrint Page

Conversation